Clinical study of Xianjun formula combined with standard western therapy in metastatic colorectal cancer

doi:10.5306/wjco.119607

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 17, Issue 6

This Article

(4)

(3)

(0)

(2)

(60)

Peer-Review Report of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Journal Information of This Article

Publication Name

World Journal of Clinical Oncology

ISSN

2218-4333

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Prospective Study

Copyright: ©Author(s) 2026. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution-NonCommercial (CC BY-NC 4.0) license. No commercial re-use. See permissions. Published by Baishideng Publishing Group Inc.

World J Clin Oncol. Jun 24, 2026; 17(6): 119607
Published online Jun 24, 2026. doi: 10.5306/wjco.119607

Open in New Tab Full Size Figure Download Figure

Figure 1 Study flow chart. OS: Overall survival; PFS: Progression-free survival; ORR: Objective response rate; DCR: Disease control rate.

Citation: Wang LF, Sun YX, Bian JY, Zhang T. Clinical study of Xianjun formula combined with standard western therapy in metastatic colorectal cancer. World J Clin Oncol 2026; 17(6): 119607
URL: https://www.wjgnet.com/2218-4333/full/v17/i6/119607.htm
DOI: https://dx.doi.org/10.5306/wjco.119607

Wang LF, Sun YX, Bian JY, Zhang T. Clinical study of Xianjun formula combined with standard western therapy in metastatic colorectal cancer. World J Clin Oncol 2026; 17(6): 119607 [DOI: 10.5306/wjco.119607]

All content on this site: Copyright © 1993-2026 Baishideng Publishing Group Inc, its licensors, and contributors. All rights are reserved, including those for text and data mining, AI training, and similar technologies. For all open access content, the relevant licensing terms apply.